Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCS6422 + Capecitabine Phase 1b in Advanced GI Tumors
NCT04861987Phase 1Completed
- Sponsor
- Processa Pharmaceuticals, Inc.
- Start
- Jun 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PCS6422 in gastrointestinal cancer, sponsored by Processa Pharmaceuticals, Inc. Primary endpoints: Dose Limiting Toxicities at 6 months, Adverse Events at 6 months and 1 more. Started Jun 2021; status: completed.
02
Drugs
PCS6422
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT04861987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04861987.